Is Reata's Friedreich's Ataxia Study a Failure?

Rare Disease ReportData from a Phase 2 Friedreich’s ataxia (FA) study by Reata Pharmaceuticals is making its rounds on social media today. The data, according to Reata, is exceptional. However, according to many on Twitter, the trial is a failure.

In spite of what the critics think, the company and the advocacy group Friedreich’s Ataxia Research Alliance (FARA) are cautiously optimistic.

About: Rare Disease Report is a website and weekly e-newsletter that offers an independent voice for the Rare Disease Community. It strives to bring together medical, scientific, investment, regulatory, and advocate professionals interested in rare diseases and orphan drugs.


NOTE: This is a news published on the web, from a news source that is usually rigorous. I usually try to publish here all the scientific news around the FA, without censorship. This means that I do not always necessary should agree with the opinions.

 Is Reata's Friedreich's Ataxia Study a Failure?